Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax
Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax have?
Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax has 18 citations in the OpenAlex counts ScholarIQ stores.
When was Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax published?
Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax has 2022 year in the ScholarIQ index.
What is the open-access status of Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax?
Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax has closed oa status in the ScholarIQ index.
What is the DOI of Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax?
The DOI for Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax is on the source record.
What is the PMID of Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax?
The PMID for Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax is on the source record.
What is the OpenAlex record for Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax?
The OpenAlex for Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax is on the source record.